Sledge G W
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Semin Oncol. 1996 Feb;23(1 Suppl 1):10-2.
Phase I and II trials to evaluate paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) as a single agent and combined with other drugs have generated considerable enthusiasm for this interesting new agent. Despite these trials, or because of them, many important questions remain regarding the use of paclitaxel. Ongoing Cooperative Oncology Group trials investigating the use of paclitaxel in breast cancer include CLB 9342, examining the question of paclitaxel dose intensity; the National Surgical Adjuvant Breast Project trial B-26, investigating the question of duration of infusion; E1193, testing the relative activity and synergy of paclitaxel and doxorubicin in a metastatic setting; and CLB 9344, focusing on the adjuvant use of paclitaxel. The cooperative groups are currently investigating novel paclitaxel-based combination therapy in phase II trials.
评估紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）作为单一药物以及与其他药物联合使用的I期和II期试验，引发了人们对这种有趣新药的极大热情。尽管进行了这些试验，或者正是因为这些试验，关于紫杉醇的使用仍存在许多重要问题。正在进行的肿瘤协作组试验中，研究紫杉醇在乳腺癌中应用的试验包括CLB 9342，该试验探讨紫杉醇剂量强度问题；国家外科辅助乳腺项目试验B - 26，研究输注持续时间问题；E1193，测试紫杉醇和阿霉素在转移情况下的相对活性和协同作用；以及CLB 9344，重点关注紫杉醇的辅助应用。目前，协作组正在II期试验中研究基于紫杉醇的新型联合疗法。
